Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 23825881)

1.

Using TRIPS flexibilities to facilitate access to medicines.

Nicol D, Owoeye O.

Bull World Health Organ. 2013 Jul 1;91(7):533-9. doi: 10.2471/BLT.12.115865. Epub 2013 Apr 18.

2.

Balancing access to pharmaceuticals with patent rights.

Nicol D.

Monash Bioeth Rev. 2003 Apr;22(2):50-62.

PMID:
15069957
3.

Removing barriers? An overview of the Canadian Access to Medicines Regime.

Penner MD, Armstrong PG.

Health Law Can. 2008 Jun;28(3-4):112-22.

PMID:
19051971
4.
5.

Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?

Oliveira MA, Bermudez JA, Chaves GC, Velásquez G.

Bull World Health Organ. 2004 Nov;82(11):815-21. Epub 2004 Dec 14.

6.

Delivering drugs to the poor: will the TRIPS Amendment help?

Dutfield G.

Am J Law Med. 2008;34(2-3):107-24. No abstract available.

PMID:
18697688
7.

TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.

't Hoen E.

Chic J Int Law. 2002 Spring;3(1):27-46. No abstract available.

PMID:
15709298
8.

Academic patents and access to medicines in developing countries.

Sampat BN.

Am J Public Health. 2009 Jan;99(1):9-17. doi: 10.2105/AJPH.2007.128769. Epub 2008 Nov 13.

9.

[Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].

Chaves GC, Oliveira MA, Hasenclever L, de Melo LM.

Cad Saude Publica. 2007 Feb;23(2):257-67. Review. Portuguese.

10.

Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?

Dionisio D, Cao Y, Hongzhou L, Kraisintu K, Messeri D.

Curr HIV Res. 2006 Jan;4(1):3-20. Review.

PMID:
16454707
11.

UK Commission concludes international patent laws hinder access to medicines in developing countries.

Elliott R.

Can HIV AIDS Policy Law Rev. 2002 Dec;7(2-3):59. English, French.

PMID:
14740605
13.

Driving a decade of change: HIV/AIDS, patents and access to medicines for all.

Hoen E', Berger J, Calmy A, Moon S.

J Int AIDS Soc. 2011 Mar 27;14:15. doi: 10.1186/1758-2652-14-15. Review.

15.

[Patents and availability of essential drugs].

Carné X.

Med Clin (Barc). 2007 Nov 3;129(16):617-8. Spanish. No abstract available.

PMID:
18001674
16.

Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options.

Reichman JH.

J Law Med Ethics. 2009 Summer;37(2):247-63. doi: 10.1111/j.1748-720X.2009.00369.x.

17.

Basic survival needs and access to medicines--coming to grips with TRIPS: conversion + calculation.

Van Puymbroeck RV.

J Law Med Ethics. 2010 Fall;38(3):520-49. doi: 10.1111/j.1748-720X.2010.00510.x.

PMID:
20880239
18.

Should access to medicines and TRIPS flexibilities be limited to specific diseases?

Outterson K.

Am J Law Med. 2008;34(2-3):279-301. No abstract available.

PMID:
18697695
19.

Lift patent barriers to increase access to medicines, says commission.

Zarocostas J.

BMJ. 2006 Apr 8;332(7545):814. No abstract available.

20.

Taking TRIPS to India--Novartis, patent law, and access to medicines.

Mueller JM.

N Engl J Med. 2007 Feb 8;356(6):541-3. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk